好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Quantitative Burst Suppression as a Biomarker in the Phase 2 Trial of SAGE-547: Lessons Learned for the First International Phase 3, Randomized, Controlled Trial for Super-Refractory Status Epilepticus (The STATUS Trial)
Epilepsy/Clinical Neurophysiology (EEG)
(-)
197
Authors/Disclosures
Eric Rosenthal, MD (Massachusetts General Hospital)
PRESENTER 		Dr. Rosenthal has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma, Inc. . Dr. Rosenthal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ceribell, Inc. . The institution of Dr. Rosenthal has received research support from Sage Therapeutics. Dr. Rosenthal has received intellectual property interests from a discovery or technology relating to health care.
Helen Colquhoun Helen Colquhoun has received personal compensation for serving as an employee of Sage Therapeutics. Helen Colquhoun has stock in Sage Therapeutics. Helen Colquhoun has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file